 |
 |
|
1 December 1996 | Volume 125 Issue 11 | Pages 873-882
Background: Body wasting, particularly loss of body cell mass, is an increasingly prevalent acquired immunodeficiency syndrome (AIDS)-defining condition and is an independent risk factor for death in patients infected with the human immunodeficiency virus (HIV). Treatment with growth hormone for 7 days resulted in weight gain and nitrogen retention, but the long-term effects of this treatment in patients with HIV-associated wasting are not known.
Objective: To evaluate the long-term effect of treatment with growth hormone on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting.
Design: Randomized, double-blind, placebo-controlled, multicenter trial.
Setting: Outpatient university and community-based patient care facilities.
Patients: 178 HIV-infected patients with a documented unintentional weight loss of at least 10% or weight less than 90% of the lower limit of ideal body weight.
Intervention: Patients were randomly assigned to receive either recombinant human growth hormone, 0.1 mg/kg of body weight per day (average dosage, 6 mg/d) (n = 90) or placebo (n = 88) for 12 weeks.
Measurements: Weight; body fat, lean body mass, and bone mineral content (measured by dual-energy x-ray absorptiometry); total body water (by deuterium oxide dilution); extracellular water (by sodium bromide dilution); work output (by treadmill exercise); quality of life; and safety of treatment.
Results: Treatment with growth hormone resulted in a sustained and statistically significant increase in weight (mean increase ±SD, 1.6 ± 3.7 kg [P < 0.001]) and lean body mass (3.0 ± 3.0 kg [P < 0.001]), accompanied by a decrease in body fat (- 1.7 ± 1.7 kg [P < 0.001]). In contrast, in patients receiving placebo, weight (increase, 0.1 ± 3.1 kg), lean body mass (decrease, 0.1 ± 2.0 kg), and body fat (decrease, 0.3 ± 2.2 kg) did not change significantly from baseline. Differences between groups at week 12 were statistically significant (P = 0.011 for body weight and P < 0.001 for lean body mass and body fat). A greater increase in treadmill work output was noted in the group receiving growth hormone (increase, 99 ± 293 kg·m/min) compared with the group receiving placebo (increase, 20 ± 233 kg·m/min) (P = 0.039). Health status (quality of life) scores did not differ between groups at baseline or after treatment. Days of disability and use of medical resources were the same for both groups. Treatment was well tolerated; no significant differences were seen between groups in clinical events, progression of AIDS, CD4+ or CD8+ cell counts, or viral burden.
Conclusion: Treatment with growth hormone increases body weight, lean body mass, and treadmill work output and appears to be a safe and potentially effective therapy in patients with HIV-associated wasting.
*For members of the Serostim Study Group, see the Appendix.
Author and Article Information
The Serostim Study Group*
ARTICLE
Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting
A Randomized, Placebo-Controlled Trial
Grant Support: By National Institutes of Health grants DK45833, DK40990, DK49448, and RR-00083 and by Serono Laboratories.
Requests for Reprints: Morris Schambelan, MD, San Francisco General Hospital, Building 100, Room 321, 1001 Potrero Avenue, San Francisco, CA 94110.
Current Author Addresses: Drs. Schambelan and Mulligan: San Francisco General Hospital, Building 100, Room 321, 1001 Potrero Avenue, San Francisco, CA 94110.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., October 1, 2008; 62(4): 648 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Falutz, S. Allas, K. Blot, D. Potvin, D. Kotler, M. Somero, D. Berger, S. Brown, G. Richmond, J. Fessel, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV N. Engl. J. Med., December 6, 2007; 357(23): 2359 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mulligan, R. Zackin, J. H. Von Roenn, M. A. Chesney, M. J. Egorin, F. R. Sattler, C. A. Benson, T. Liu, T. Umbleja, S. Shriver, et al. Testosterone Supplementation of Megestrol Therapy Does Not Enhance Lean Tissue Accrual in Men with Human Immunodeficiency Virus-Associated Weight Loss: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Comparison of Body Composition Assessment Methods in Patients with Human Immunodeficiency Virus-Associated Wasting Receiving Growth Hormone J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2952 - 2959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Tisdale Clinical Anticachexia Treatments Nutr Clin Pract, April 1, 2006; 21(2): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Thomas Guidelines for the Use of Orexigenic Drugs in Long-Term Care Nutr Clin Pract, February 1, 2006; 21(1): 82 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Perls, N. R. Reisman, and S. J. Olshansky Provision or Distribution of Growth Hormone for "Antiaging": Clinical and Legal Issues JAMA, October 26, 2005; 294(16): 2086 - 2090. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E494 - E503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Storer, L. J. Woodhouse, F. Sattler, A. B. Singh, E. T. Schroeder, K. Beck, M. Padero, P. Mac, K. E. Yarasheski, P. Geurts, et al. A Randomized, Placebo-Controlled Trial of Nandrolone Decanoate in Human Immunodeficiency Virus-Infected Men with Mild to Moderate Weight Loss with Recombinant Human Growth Hormone as Active Reference Treatment J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4474 - 4482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Kopple, G. Brunori, M. Leiserowitz, and D. Fouque Growth hormone induces anabolism in malnourished maintenance haemodialysis patients Nephrol. Dial. Transplant., May 1, 2005; 20(5): 952 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mulligan, R. Zackin, R. A. Clark, B. Alston-Smith, T. Liu, F. R. Sattler, T. B. Delvers, J. S. Currier, and for the AIDS Clinical Trials Group 329 Study Team Effect of Nandrolone Decanoate Therapy on Weight and Lean Body Mass in HIV-Infected Women With Weight Loss: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial Arch Intern Med, March 14, 2005; 165(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Growth Hormone (GH) Responses to GH-Releasing Hormone-Arginine Testing in Human Immunodeficiency Virus Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Esposito, S. G. Thomas, L. Kingdon, and S. Ezzat Growth Hormone Treatment Improves Peripheral Muscle Oxygen Extraction-Utilization during Exercise in Patients with Human Immunodeficiency Virus-Associated Wasting: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5124 - 5131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J van der Lely Justified and unjustified use of growth hormone Postgrad. Med. J., October 1, 2004; 80(948): 577 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, M. Torriani, J. Kissko, and S. Grinspoon Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial JAMA, July 14, 2004; 292(2): 210 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahele and K. Fearon Research methodology: cancer cachexia syndrome Palliative Medicine, July 1, 2004; 18(5): 409 - 417. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A Wainberg, B. G. Brenner, E. Daar, J. M. Gertner, C. Olivier, and S. Kenley Lack of Effect of Recombinant Human Growth Hormone on the In Vitro Activities of Antiretroviral Drugs against Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2337 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carlo-Stella, M. Di Nicola, R. Milani, A. Guidetti, M. Magni, M. Milanesi, P. Longoni, P. Matteucci, F. Formelli, F. Ravagnani, et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers Blood, May 1, 2004; 103(9): 3287 - 3295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dolan, S. Wilkie, N. Aliabadi, M. P. Sullivan, N. Basgoz, B. Davis, and S. Grinspoon Effects of Testosterone Administration in Human Immunodeficiency Virus-Infected Women With Low Weight: A Randomized Placebo-Controlled Study Arch Intern Med, April 26, 2004; 164(8): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Frost and C. H. Lang Alteration of somatotropic function by proinflammatory cytokines J Anim Sci, January 1, 2004; 82(13_suppl): E100 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Schibler, R von der Heiden, P Birrer, and P E Mullis Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis Arch. Dis. Child., December 1, 2003; 88(12): 1078 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. S. Leow, C. L. Addy, and C. S. Mantzoros Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Frost, G. J. Nystrom, and C. H. Lang Tumor Necrosis Factor-{alpha} Decreases Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Expression in C2C12 Myoblasts via a Jun N-Terminal Kinase Pathway Endocrinology, May 1, 2003; 144(5): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Hall, A. Bartke, and J. M. Martinko Humoral Immune Response in Mice Over-expressing or Deficient in Growth Hormone Experimental Biology and Medicine, July 1, 2002; 227(7): 535 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grinspoon and M. Gelato Editorial: The Rational Use of Growth Hormone in HIV-Infected Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3478 - 3479. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lo, K. Mulligan, M. A. Noor, J.-M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3480 - 3487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ritz, the Investigators of the Source Study, of the Human Nutrition Research, and Centre-Auvergne Chronic Cellular Dehydration in the Aged Patient J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2001; 56(6): M349 - M352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-M. G. Wilson Guest Editorial: Bitter-Sweet Memories: Truth and Fiction J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2001; 56(4): 196M - 199. [Full Text]
|
|
|
|
 |
|
 D. P. Kotler Cachexia Ann Intern Med, October 17, 2000; 133(8): 622 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Casaburi Skeletal Muscle Function in COPD Chest, May 1, 2000; 117(5_suppl_1): 267S - 271S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schwenk, A. Beisenherz, G. Kremer, V. Diehl, B. Salzberger, and G. Fatkenheuer Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment Am. J. Clinical Nutrition, November 1, 1999; 70(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-S. Yeh and M. W Schuster Geriatric cachexia: the role of cytokines Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF]
|
|
|
|
|
|
A. Strawford, T. Barbieri, M. Van Loan, E. Parks, D. Catlin, N. Barton, R. Neese, M. Christiansen, J. King, and M. K. Hellerstein Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1282 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): S2 - 40. [Full Text] [PDF]
|
|
|
|
|
|
S. Grinspoon, C. Corcoran, D. Rosenthal, T. Stanley, K. Parlman, M. Costello, M. Treat, S. Davis, B. Burrows, N. Basgoz, et al. Quantitative Assessment of Cross-Sectional Muscle Area, Functional Status, and Muscle Strength in Men with the Acquired Immunodeficiency Syndrome Wasting Syndrome J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 201 - 206. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. R. Bistrian Dietary Treatment in Secondary Wasting and Cachexia J. Nutr., January 1, 1999; 129(1): 290S - 290S. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. McNurlan, P. J. Garlick, R. A. Frost, K. A. DeCristofaro, C. H. Lang, R. T. Steigbigel, J. Fuhrer, and M. Gelato Albumin Synthesis and Bone Collagen Formation in Human Immunodeficiency Virus-Positive Subjects: Differential Effects of Growth Hormone Administration J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3050 - 3055. [Abstract] [Full Text]
|
|
|
|
|
|
S. Bhasin, T. W. Storer, N. Asbel-Sethi, A. Kilbourne, R. Hays, I. Sinha-Hikim, R. Shen, S. Arver, and G. Beall Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3155 - 3162. [Abstract] [Full Text]
|
|
|
|
|
|
K. Miller, C. Corcoran, C. Armstrong, K. Caramelli, E. Anderson, D. Cotton, N. Basgoz, L. Hirschhorn, R. Tuomala, D. Schoenfeld, et al. Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2717 - 2725. [Abstract] [Full Text]
|
|
|
|
|
|
K. Mulligan, V. W. Tai, and M. Schambelan Effects of Chronic Growth Hormone Treatment on Energy Intake and Resting Energy Metabolism in Patients with Human Immunodeficiency Virus-Associated Wasting--A Clinical Research Center Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1542 - 1547. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. E. Mulroney, K. J. McDonnell, C. B. Pert, M. R. Ruff, Z. Resch, W. K. Samson, and M. D. Lumpkin HIV gp120 inhibits the somatotropic axis: A possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting PNAS, February 17, 1998; 95(4): 1927 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marcus M.D. and G. M. Reaven M.D. Growth Hormone--Ready for Prime Time? J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 725 - 726. [Full Text] [PDF]
|
|
|
|
 |
|
 Growth Hormone and Wasting AIDS Clinical Care, January 1, 1997; 1997(101): 2 - 2. [Full Text]
|
|
|
|
 |
|
 MIXED NEWS ON GROWTH HORMONE Journal Watch (General), December 13, 1996; 1996(1213): 1 - 1. [Full Text]
|
|
Article
